Your browser is no longer supported. Please, upgrade your browser.
GNCA [NASD]
Genocea Biosciences, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own8.23% Shs Outstand69.81M Perf Week-4.97%
Market Cap57.99M Forward P/E- EPS next Y-0.71 Insider Trans0.00% Shs Float52.72M Perf Month-1.04%
Income-34.90M PEG- EPS next Q-0.20 Inst Own60.90% Short Float3.04% Perf Quarter-44.84%
Sales1.60M P/S36.24 EPS this Y47.90% Inst Trans- Short Ratio2.93 Perf Half Y-52.95%
Book/sh0.54 P/B1.78 EPS next Y-47.90% ROA-43.00% Target Price6.12 Perf Year-68.32%
Cash/sh0.81 P/C1.19 EPS next 5Y- ROE-265.30% 52W Range0.91 - 4.05 Perf YTD-17.26%
Dividend- P/FCF- EPS past 5Y41.10% ROI-191.80% 52W High-76.27% Beta1.39
Dividend %- Quick Ratio3.40 Sales past 5Y15.20% Gross Margin- 52W Low5.46% ATR0.09
Employees72 Current Ratio3.40 Sales Q/Q220.00% Oper. Margin- RSI (14)34.59 Volatility5.39% 9.41%
OptionableYes Debt/Eq0.26 EPS Q/Q36.80% Profit Margin- Rel Volume0.42 Prev Close1.01
ShortableYes LT Debt/Eq0.14 EarningsOct 28 BMO Payout- Avg Volume547.19K Price0.96
Recom1.40 SMA20-13.43% SMA50-21.64% SMA200-48.98% Volume229,903 Change-4.97%
Nov-15-19Initiated SVB Leerink Outperform $7
Jul-08-19Resumed Stifel Buy $13
Mar-01-19Reiterated Needham Buy
Feb-06-18Upgrade Needham Hold → Buy $3
Sep-27-17Downgrade Needham Buy → Hold
Sep-26-17Downgrade Stifel Buy → Hold $15 → $2.50
Jul-25-17Upgrade Needham Hold → Buy $12
Feb-17-17Downgrade Needham Buy → Hold
Apr-01-16Reiterated Stifel Buy $11 → $13
Dec-17-15Initiated UBS Buy $15
Oct-20-15Reiterated Needham Buy $22 → $15
Oct-19-15Reiterated FBR Capital Outperform $20 → $17
Mar-05-14Initiated Needham Buy $22
Mar-03-14Initiated Stifel Buy $25
Jan-06-22 05:36AM  
Jan-05-22 05:46PM  
Jan-04-22 07:00AM  
Dec-23-21 07:36AM  
Nov-10-21 07:26PM  
Oct-28-21 07:00AM  
Oct-21-21 04:30PM  
Sep-28-21 04:30PM  
Sep-13-21 04:52PM  
Sep-07-21 07:40PM  
Aug-23-21 08:36AM  
Jul-29-21 07:00AM  
Jul-22-21 05:05PM  
Jul-14-21 09:52AM  
Jul-13-21 10:11AM  
07:30AM  
Jul-07-21 08:38AM  
Jun-17-21 05:30AM  
Jun-04-21 09:00AM  
May-30-21 04:55AM  
Apr-29-21 08:55AM  
07:00AM  
06:30AM  
Apr-22-21 04:30PM  
Apr-10-21 08:30AM  
Apr-06-21 04:30PM  
Mar-02-21 04:01PM  
Feb-11-21 07:30AM  
06:30AM  
Feb-04-21 04:05PM  
Jan-28-21 06:00AM  
Jan-19-21 06:54PM  
Jan-04-21 04:19PM  
Dec-28-20 08:42AM  
Dec-21-20 01:24AM  
Dec-10-20 07:54PM  
Nov-12-20 08:00AM  
Nov-09-20 08:01AM  
Nov-05-20 06:10PM  
Oct-29-20 07:00AM  
06:30AM  
Oct-28-20 03:30PM  
Oct-22-20 04:57PM  
09:46AM  
Oct-15-20 11:30AM  
Oct-14-20 05:22PM  
Sep-23-20 11:40AM  
Sep-22-20 09:05AM  
07:30AM  
Sep-17-20 03:00AM  
Sep-15-20 08:07AM  
Sep-03-20 06:53PM  
Jul-30-20 07:00AM  
Jul-23-20 07:00AM  
Jul-22-20 09:02AM  
Jul-20-20 08:00AM  
Jul-16-20 08:00AM  
Jul-06-20 09:27AM  
Jun-23-20 03:52PM  
Jun-22-20 09:00AM  
Jun-15-20 07:30AM  
May-29-20 08:00AM  
May-19-20 07:30AM  
May-13-20 06:02PM  
07:40AM  
May-12-20 05:32PM  
May-11-20 04:30PM  
May-05-20 04:05PM  
Apr-30-20 07:00AM  
Apr-24-20 06:11AM  
Apr-23-20 08:01PM  
11:44AM  
Apr-21-20 07:00AM  
Apr-08-20 04:01PM  
Feb-26-20 04:05PM  
Feb-20-20 09:15PM  
08:00AM  
Feb-13-20 07:00AM  
Feb-06-20 07:30AM  
Dec-14-19 09:43PM  
Nov-14-19 05:00PM  
08:30AM  
Nov-09-19 09:00AM  
Nov-05-19 08:05AM  
Oct-29-19 07:22AM  
Oct-24-19 07:00AM  
Oct-17-19 08:00AM  
Sep-30-19 01:13PM  
Sep-27-19 08:00AM  
Sep-18-19 09:31AM  
Aug-30-19 08:00AM  
Aug-24-19 01:46PM  
Aug-05-19 01:13PM  
Jul-25-19 07:00AM  
Jul-18-19 08:00AM  
Jun-25-19 08:37AM  
Jun-24-19 01:58PM  
Jun-20-19 09:52AM  
Jun-18-19 04:04PM  
Jun-03-19 12:47PM  
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clark William DPresident and CEOFeb 17Option Exercise2.2436,49881,78563,750Feb 18 11:25 AM